4D Molecular Therapeutics, Inc.
FDMT
$10.45
$0.111.06%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -96.42% | 94,444.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -96.42% | 94,444.44% | |||
| Cost of Revenue | 12.99% | 21.74% | |||
| Gross Profit | -324.54% | 158.50% | |||
| SG&A Expenses | -8.46% | 7.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 9.10% | 18.96% | |||
| Operating Income | -596.93% | 125.12% | |||
| Income Before Tax | -454.49% | 134.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -454.49% | 134.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -454.49% | 134.10% | |||
| EBIT | -596.93% | 125.12% | |||
| EBITDA | -551.32% | 127.77% | |||
| EPS Basic | -432.85% | 129.95% | |||
| Normalized Basic EPS | -431.27% | 131.31% | |||
| EPS Diluted | -432.85% | 129.95% | |||
| Normalized Diluted EPS | -431.27% | 131.31% | |||
| Average Basic Shares Outstanding | 6.49% | 13.88% | |||
| Average Diluted Shares Outstanding | 6.49% | 13.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||